EHEric P. Hanson

Eric P. Hanson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric P. Hanson has a total of 165 co-authors. Here are the top co-authors by number of shared publications:

  • Jordan S. Orange

    Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, Columbia University, New York, NY

    6 shared publications
  • Alex W. Wessel

    Immunodeficiency and Inflammatory Disease Unit and

    2 shared publications
  • Ashish Jain

    Laboratory of Host Defenses, Clinical Immunology Unit, National Institute of Allergy and Infectious Diseases Bethesda, MD, USA

    2 shared publications
  • Gulbu Uzel

    Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, 8Laboratory of Allergic Diseases, 9Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases; 10National Center for Biotechnology Information; 11National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Insitutes of Health, Bethesda, MD 20892

    2 shared publications
  • James A. Johnston

    DNAX Research Institute, 901 California Avenue, Palo Alto, CA, 94304, USA

    2 shared publications
  • Jevgenia Zilberman-Rudenko

    Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA; Departments of Biomedical Engineering and Medicine, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA

    2 shared publications

Latest Publications

  • Open Access

    Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor

    by Simon J. Shaw, Vanessa C. Taylor, Jonathan T. Sims, Stephen Ho, Chrystelle Lamagna, Lucy Yan, Nicholas C. Reising, Andrew Chow, Eric P. Hanson, Andrew C. Vendel, et al.

    Receptor‐interacting serine/threonine‐protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib is a potent and selective allosteric inhibitor of RIPK1 and is currently being studied in clinical trials. Here, we present data on the development of ocadusertib, including preclinical studies and pharmacokinetic, safety, and target engagement results from phase 1 trials. Preclinically, ocadusertib inhibited RIPK1 enzymatic activity with high potency (half‐maximal inhibitory concentration [IC 50 ] = 12–38 nM) and inhibited necroptotic responses in multiple cell‐based assays. Ocadusertib was highly selective for RIPK1, showing no significant inhibition of more than 100 other kinases representative of the full kinome. In mouse studies, ocadusertib treatment prevented RIPK1‐dependent hypothermia in response to tumor necrosis factor (TNF) challenge and significantly reduced disease severity in a model of chronic proliferative dermatitis. In a first‐in‐human study of ocadusertib in healthy participants, single oral doses exhibited linear pharmacokinetics and dose‐proportional exposure, with a time to maximum concentration of 1–4 h and a half‐life of 13–15 h. Steady state was attained at 4–6 days after multiple once‐daily dose administrations. Ocadusertib was well tolerated, with no deaths, serious adverse events, or significant treatment‐emergent adverse events reported. In a phase 1, double‐blind, randomized, multiple‐dose study in healthy participants, greater than 90% RIPK1 target engagement was achieved at Day 14 with ocadusertib treatment. Taken together, these findings support further assessment of ocadusertib for the treatment of chronic inflammatory diseases.


  • Open Access

    Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway

    by Heeseog Kang, Smita Jha, Aleksandra Ivovic, Nadja Fratzl-Zelman, Zuoming Deng, Apratim Mitra, Wayne A. Cabral, Eric P. Hanson, Eileen Lange, Edward W. Cowen, et al.

    Melorheostosis is a rare sclerosing dysostosis characterized by asymmetric exuberant bone formation. Recently, we reported that somatic mosaicism for MAP2K1-activating mutations causes radiographical “dripping candle wax” melorheostosis. We now report somatic SMAD3 mutations in bone lesions of four unrelated patients with endosteal pattern melorheostosis. In vitro, the SMAD3 mutations stimulated the TGF-β pathway in osteoblasts, enhanced nuclear translocation and target gene expression, and inhibited proliferation. Osteoblast differentiation and mineralization were stimulated by the SMAD3 mutation, consistent with higher mineralization in affected than in unaffected bone, but differing from MAP2K1 mutation–positive melorheostosis. Conversely, osteoblast differentiation and mineralization were inhibited when osteogenesis of affected osteoblasts was driven in the presence of BMP2. Transcriptome profiling displayed that TGF-β pathway activation and ossification-related processes were significantly influenced by the SMAD3 mutation. Co-expression clustering illuminated melorheostosis pathophysiology, including alterations in ECM organization, cell growth, and interferon signaling. These data reveal antagonism of TGF-β/SMAD3 activation by BMP signaling in SMAD3 mutation–positive endosteal melorheostosis, which may guide future therapies.


  • Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease

    by Jevgenia Zilberman-Rudenko, Linda Monaco Shawver, Alex W. Wessel, Yongquan Luo, Martin Pelletier, Wanxia Li Tsai, Younglang Lee, Spiridon Vonortas, Laurence Cheng, Jonathan D. Ashwell, et al.

    Significance: Regulated activation of the NF-κB family of transcription factors is important for normal development, immune cell function, and inflammatory responses. NEMO, the NF-κB essential modulator, controls activation of the canonical IKK complex and NF-κB–mediated cellular responses, but details of how this is achieved are not fully known. Our results show that C-terminal mutations in NEMO can cause hyperactivation of inflammatory responses to Toll-like receptor and TNF ligands through impaired recruitment of the negative NF-κB regulator A20/TNFAIP3. Our results help to explain the inflammatory symptoms in patients harboring these NEMO mutations. Furthermore, our findings suggest that targeting this molecular interaction by enhancing A20 expression or its recruitment to the NEMO C-terminus may be a therapeutic strategy for human inflammatory disease.


  • Top Cited Papers
    Open Access

    Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease

    by Qing Zhou, Hongying Wang, Daniella M Schwartz, Monique Stoffels, Yong Hwan Park, Yuan Zhang, Dan Yang, Erkan Demirkaya, Masaki Takeuchi, Wanxia Li Tsai, et al.

    Ivona Aksentijevich and colleagues identify heterozygous loss-of-function mutations in TNFAIP3 (encoding A20) in six unrelated families with early-onset systemic inflammation. Affected individuals exhibit increased expression of NF-κB–mediated proinflammatory cytokines, consistent with the established role of A20 as a potent inhibitor of the NF-κB signaling pathway. Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity1. Herein we describe a new disease caused by high-penetrance heterozygous germline mutations in TNFAIP3, which encodes the NF-κB regulatory protein A20, in six unrelated families with early-onset systemic inflammation. The disorder resembles Behçet's disease, which is typically considered a polygenic disorder with onset in early adulthood2. A20 is a potent inhibitor of the NF-κB signaling pathway3. Mutant, truncated A20 proteins are likely to act through haploinsufficiency because they do not exert a dominant-negative effect in overexpression experiments. Patient-derived cells show increased degradation of IκBα and nuclear translocation of the NF-κB p65 subunit together with increased expression of NF-κB–mediated proinflammatory cytokines. A20 restricts NF-κB signals via its deubiquitinase activity. In cells expressing mutant A20 protein, there is defective removal of Lys63-linked ubiquitin from TRAF6, NEMO and RIP1 after stimulation with tumor necrosis factor (TNF). NF-κB–dependent proinflammatory cytokines are potential therapeutic targets for the patients with this disease.


  • A Method for the Quantitative Analysis of Stimulation-Induced Nuclear Translocation of the p65 Subunit of NF-κB from Patient-Derived Dermal Fibroblasts

    by Alex W. Wessel, Eric P. Hanson

    Developmental and immune-mediated disease has been linked to genetic mutation of key signaling components involved in NF-κB activation that leads to impaired activation or regulation of the canonical IKK complex. We identify patients with suspected or known defects of the NF-κB signaling pathway through clinical phenotyping and genetic sequencing. To help understand how mutations cause disease, we quantitate the kinetics and dose-response of NF-κB activation signaling events in their cells. Following activation of the canonical IKK complex, phosphorylation of the inhibitor of NF-κB proteins (IκB) leads to their degradation and the subsequent translocation of NF-κB family members from the cell cytoplasm to the nucleus. Here, we provide a method to obtain patient-derived dermal fibroblasts and quantitatively assess the integrity of the signal transduction pathway from receptor activation to nuclear p65 translocation.


  • Signal transduction in immune cells

    by Eric P. Hanson, Daniella Muallem Schwartz, Michael Bonelli, John J. O'Shea, Martin Aringer

  • 278

    by Alex W. Wessel, Amy P. Hsu, Jevgenia Zilberman-Rudenko, Raphaela T. Goldbach-Mansky, Richard M. Siegel, Eric P. Hanson

  • Open Access

    Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome

    by Daniel Kotlarz, Natalia Ziętara, Gulbu Uzel, Thomas Weidemann, Christian J. Braun, Jana Diestelhorst, Peter M. Krawitz, Peter N. Robinson, Jochen Hecht, Jacek Puchałka, et al.

    Primary immunodeficiencies (PIDs) represent exquisite models for studying mechanisms of human host defense. In this study, we report on two unrelated kindreds, with two patients each, who had cryptosporidial infections associated with chronic cholangitis and liver disease. Using exome and candidate gene sequencing, we identified two distinct homozygous loss-of-function mutations in the interleukin-21 receptor gene (IL21R; c.G602T, p.Arg201Leu and c.240_245delCTGCCA, p.C81_H82del). The IL-21RArg201Leu mutation causes aberrant trafficking of the IL-21R to the plasma membrane, abrogates IL-21 ligand binding, and leads to defective phosphorylation of signal transducer and activator of transcription 1 (STAT1), STAT3, and STAT5. We observed impaired IL-21–induced proliferation and immunoglobulin class-switching in B cells, cytokine production in T cells, and NK cell cytotoxicity. Our study indicates that human IL-21R deficiency causes an immunodeficiency and highlights the need for early diagnosis and allogeneic hematopoietic stem cell transplantation in affected children.


  • Congenital alterations of NEMO glutamic acid 223 result in hypohidrotic ectodermal dysplasia and immunodeficiency with normal serum IgG levels

    by Gital Karamchandani-Patel, Eric P. Hanson, Rushani Saltzman, C. Eve Kimball, Ricardo U. Sorensen, Jordan S. Orange


  • Open Access

    Hypohidrotic Ectodermal Dysplasia and Immunodeficiency with Coincident NEMO and EDA Mutations

    by Michael D. Keller, Maureen Petersen, Peck Ong, Joseph Church, Kimberly Risma, Jon Burham, Ashish Jain, E. Richard Stiehm, Eric P. Hanson, Gulbu Uzel, et al.

    Ectodermal dysplasias (ED) are uncommon genetic disorders resulting in abnormalities in ectodermally derived structures. Many ED-associated genes have been described, of which ectodysplasin-A (EDA) is one of the more common. The NF-κB essential modulator (NEMO encoded by the IKBKG gene) is unique in that mutations result in severe humoral and cellular immunologic defects in addition to ED. We describe three unrelated kindreds with defects in both EDA and IKBKG resulting from X-chromosome crossover. This demonstrates the importance of thorough immunologic consideration of patients with ED even when an EDA etiology is confirmed, and raises the possibility of a specific phenotype arising from coincident mutations in EDA and IKBKG.